We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+10.35%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$113M
AUM Growth
-$2.14M
(-1.9%)
Cap. Flow
-$5.51M
Cap. Flow
% of AUM
-4.87%
Top 10 Holdings %
Top 10 Hldgs %
14.17%
Holding
280
New
34
Increased
61
Reduced
100
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Financials Index ETF
FNCL
|
+$1.46M |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.13M |
| 3 |
MediciNova
MNOV
|
+$969K |
| 4 |
ADVM
Adverum Biotechnologies
ADVM
|
+$866K |
| 5 |
CLSD
Clearside Biomedical
CLSD
|
+$856K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Information Technology Index ETF
FTEC
|
+$2.78M |
| 2 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$1.32M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$1.22M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$1.01M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$938K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.9% |
| 2 | Financials | 0.8% |
| 3 | Technology | 0.58% |
| 4 | Consumer Discretionary | 0.4% |
| 5 | Energy | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
76
DELISTED
Seagen Inc. Common Stock
SGEN
| $740K | 0.65% |
11,148
-6,332
| -36% | -$363K |
|
77
CytomX Therapeutics
CTMX
$705M
| $739K | 0.65% |
32,334
-2,542
| -7% | -$64.9K |
|
|
KDNY
78
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $738K | 0.65% |
21,080
+2,600
| +14% | +$99.7K |
|
|
STML
79
DELISTED
Stemline Therapeutics, Inc.
STML
| $736K | 0.65% |
45,850
-5,828
| -11% | -$104K |
|
|
SGMO
80
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $734K | 0.65% |
51,691
+5,242
| +11% | +$87.1K |
|
81
Voyager Therapeutics
VYGR
$187M
| $733K | 0.65% |
37,502
-15,905
| -30% | -$314K |
|
|
AIMT
82
DELISTED
Aimmune Therapeutics
AIMT
| $733K | 0.65% |
27,252
+5,151
| +23% | +$158K |
|
83
Xencor
XNCR
$1.44B
| $732K | 0.65% |
19,772
-15,782
| -44% | -$544K |
|
|
MDCO
84
DELISTED
Medicines Co
MDCO
| $730K | 0.65% |
19,897
-13,374
| -40% | -$435K |
|
85
Direxion Daily Utilities Bull 3X ETF
UTSL
$47.9M
| $727K | 0.64% |
+28,402
| New | +$661K |
|
|
FPRX
86
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $727K | 0.64% |
46,007
+9,879
| +27% | +$172K |
|
|
CELG
87
DELISTED
Celgene Corp
CELG
| $727K | 0.64% |
9,159
+845
| +10% | +$70.2K |
|
|
PGNX
88
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $725K | 0.64% |
+90,177
| New | +$688K |
|
|
CLVS
89
DELISTED
Clovis Oncology, Inc.
CLVS
| $724K | 0.64% |
15,930
+1,827
| +13% | +$88.9K |
|
90
Akebia Therapeutics
AKBA
$327M
| $723K | 0.64% |
72,408
+21,946
| +43% | +$220K |
|
91
United Therapeutics
UTHR
$26.3B
| $723K | 0.64% |
6,394
-314
| -5% | -$34.5K |
|
92
Neurocrine Biosciences
NBIX
$17.7B
| $717K | 0.63% |
7,296
-5,603
| -43% | -$502K |
|
|
RETA
93
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $716K | 0.63% |
20,484
-9,604
| -32% | -$293K |
|
94
Geron
GERN
$911M
| $714K | 0.63% |
208,093
-171,337
| -45% | -$654K |
|
95
Travere Therapeutics
TVTX
$5.33B
| $714K | 0.63% |
26,176
-15,627
| -37% | -$416K |
|
96
Cytokinetics
CYTK
$11B
| $713K | 0.63% |
85,880
-7,429
| -8% | -$61.8K |
|
97
PTC Therapeutics
PTCT
$6.37B
| $713K | 0.63% |
21,140
-25,777
| -55% | -$804K |
|
|
DOVA
98
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $707K | 0.63% |
23,637
+410
| +2% | +$11.2K |
|
|
ONC
99
BeOne Medicines Ltd
ONC
$33.8B
| $705K | 0.62% |
4,587
-3,495
| -43% | -$623K |
|
|
DVAX
100
DELISTED
Dynavax Technologies
DVAX
| $700K | 0.62% |
45,914
-1,984
| -4% | -$34.3K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2018 Portfolio in Review
As of Q2 2018, Virtus ETF Advisers held 280 positions worth $113M, down 1.9% from $115M the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Virtus ETF Advisers withdrew a net $5.51M in Q2 2018, closing 19 positions and reducing 100 holdings. Its most notable exit was Jounce Therapeutics, Inc. Common Stock, an estimated $1.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 79% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in Fidelity MSCI Financials Index ETF worth $1.41M.
- Virtus ETF Advisers's largest Q2 2018 buy was Fidelity MSCI Financials Index ETF: 35,927 shares worth $1.41M.
- Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q2 2018, an estimated $1.13M increase.
- Virtus ETF Advisers's biggest Q2 2018 reduction was Fidelity MSCI Information Technology Index ETF, cutting an estimated $2.78M.
- Virtus ETF Advisers fully exited Jounce Therapeutics, Inc. Common Stock in Q2 2018, selling an estimated $1.32M.
- Virtus ETF Advisers's ten largest holdings make up 14% of its $113M portfolio in Q2 2018.
- Virtus ETF Advisers opened 34 new positions and closed 19 in Q2 2018.
- Virtus ETF Advisers's portfolio value fell 1.9% quarter-over-quarter to $113M.
Based on Virtus ETF Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.